Good read but the 505(b)(2) for NB1222 is understated in your analysis for how much value it brings to shareholders.
Formulation development is well underway for NB1222 and approval for the 505 (b) (2) will expedite the process immediately to Phase 2 trials (while conducting phase 1 in non-clinical studies). Also in some instances, Phase 3 trials are not neccessary since they rely on previous data, however I'd expect a small phase 3 trial to not get ahead of ourselves. See below info: https://camargopharma.com/what-is-505b2/
This indication is also not something that needs 52 week or even 24 week analysis, so trials will be on the speedier side in the typical 505(b)(2) world.
The market cap should trade significantly higher if this NDA is accepted. I resist using the term rocket ship, but jumping from the completely unknown to Phase 2 trials could prove to do so.
All while there will be additional updates in the fall on the following:
Thank you. I've had a lot of family things to take care of so I haven't been on the board at all. Someone commented on Seeking Alpha that the plant is more effective than synthetics. When compared to Marinol that's true but it won't be compared to what's coming. Nemus' formulation for pain will be much safer and more effective than anything derived from the plant. Drugs from other companies will as well. And certain indications will never be as effective or even useful with the plant like in the case of glaucoma. Safety is just as important as efficacy and synthetics will be the only way to truly have both.
The suppository will skip to Phase 2 and need to go through Phase 3. Figure around 2 years if all goes well. Marinol isn't effective for most people for reasons we've discussed and therefore not widely prescribed. The suppository will be but it won't be a blockbuster drug. But if it's valued at a couple hundred million $$ then that's not bad for a few years work knowing it will get approved because it's already approved orally. The thinking is that it's the fastest way to either generate some revenue or get a partnership deal compared to the others in the pipeline. They're just trying to build value with everything they do and they have short term and long term goals. Meeting the short term goals enables them to keep working on the long term goals and to make it attractive for a buyout.
I'm not too worried about the Schneider deal. I think it will happen and they can certainly raise a couple million if they need to. I can't speak for the group in Europe but the people here are solid. I haven't heard anyone is panicking. Everyone on the Board had to vet this deal so I'd be shocked if they all missed something. However, anything is possible.
I'm still floored Nemus has the valuation it has. It's still the lowest of every company in cannabis or cannabinoids. Lower than all the scam companies. They're just a low key group handling their business.
News 
Market Data 
Discover 
